Home » FDA Warns Biotek for Marketing Misbranded Drugs, GMP Violations
FDA Warns Biotek for Marketing Misbranded Drugs, GMP Violations
Drugs Inspections and Audits
FDA issued a warning letter to Biotek after a review of its website found some of its products were intended for use as drugs.
The company, based in Layton, Utah, claimed one product could protect against toxic reaction and heavy metal poisoning and another helped with restless leg syndrome and muscle cramps.
The FDA did not find the products to be safe or effective for their intended uses and declared them misbranded.